Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Neutral 0

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

AI-generated analysis

πŸ“… Regeneron Pharmaceuticals (REGN) participated in the Bank of America Global Healthcare Conference 2026 on May 12, 2026.

πŸ—£οΈ The company was represented by SVP of Investor Relations Ryan Crowe and EVP of Commercial Marion McCourt.

🀝 A new government pricing and tariff agreement offers relief through January 2029.

πŸ›‘οΈ Under the new deal, Regeneron will not be subject to future government pricing mandates.

πŸ‡ΊπŸ‡Έ The tariff and pricing agreement applies specifically to products wholly owned by Regeneron in the United States.

❌ Alliance products are excluded from the scope of this specific regulatory construct.

πŸ’Š EYLEA and EYLEA HD are confirmed as wholly-owned products within the U.S.

⚠️ DUPIXENT is not considered a wholly-owned product in the U.S. under current agreements.

πŸ”’ Management declined to comment on specific exclusions beyond ownership status due to confidentiality.

Bullish Signals
  • Regeneron secured tariff relief through at least January of 2029, providing a favorable regulatory construct for its products.
  • The company confirmed it wholly owns EYLEA and EYLEA HD in the U.S., ensuring full control over these key revenue-generating assets.
Risk Factors
  • The potential for future government pricing mandates remains a risk despite the company's claims, as no guarantee against such measures was explicitly offered.
Full Analysis
Regeneron Pharmaceuticals (REGN) held a presentation at the Bank of America Global Healthcare Conference on May 12, 2026, with EVP of Commercial Marion McCourt and SVP of Investor Relations Ryan Crowe. A significant portion of the discussion focused on government pricing mandates and tariff relief agreements, specifically noting that the company would not be subject to future pricing mandates and would receive tariff relief through at least January 2029. The executives clarified that these terms apply to products wholly owned by Regeneron in the United States, which excludes certain alliance products from the agreement. When questioned about specific product inclusion, the speakers stated they cannot name products due to confidentiality but confirmed that EYLEA and EYLEA HD are wholly owned in the U.S., whereas DUPIXENT is not wholly owned in the U.S. The transcript highlights a key distinction between Regeneron's wholly owned portfolio and its alliance products regarding future regulatory and trade policies. This suggests that strategic decisions regarding pricing and tariffs will be segmented based on ownership structure, potentially differentiating the commercial outlook for EYLEA versus DUPIXENT under these new agreements. The conference segment was intended to cover a 30-minute window but included an audio gap early in the recording. Overall, the content provides specific insight into how regulatory and trade headwinds or benefits are being negotiated at the corporate level within Regeneron's business segments during this future date.